Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
<h4>Background</h4> <p>Patients with impaired glucose tolerance have an elevated risk of cardiovascular (CV) death; however, the causes and risk factors associated with non-CV deaths are poorly understood.</p> <h4>Methods</h4> <p>The NAVIGATOR trial enrolle...
| Główni autorzy: | , , , , , , |
|---|---|
| Format: | Journal article |
| Język: | English |
| Wydane: |
Elsevier
2016
|